Abstract Details

Title Incidence and Prevalence of Myasthenia Gravis: Analysis of a US Commercial Insurance Claims Database

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P4 - Poster Session 4 (11:45 AM-12:45 PM)

Poster/Presentation
Number 11-016

Objective To estimate the prevalence and incidence of myasthenia gravis (MG) in the United States (US) and describe patient demographics.

Background MG is an autoimmune disease mediated by antibodies disrupting various postsynaptic components at the neuromuscular junction. Estimates of the prevalence and incidence of MG in the US vary and robust studies describing this population are lacking.

Design/Methods This retrospective study used Inovalon data from 2016 through 2020, covering nearly 170 million lives and containing professional and institutional medical claims from Commercial, Medicare Advantage, and Medicaid payers. Confirmation of MG diagnosis was made using a previously validated, peer-reviewed methodology. We conducted a prevalence estimation in 2019 and an incidence estimation across 2018 and 2019. MG diagnoses, age at initial diagnosis, gender, comorbidities, race, and ethnicity were analyzed.

Results For the prevalence estimation, 14,373 patients with MG were identified. Extrapolating this to the US population using census data gives an estimate of 116,255 patients living with MG in the US. For patients 18 and over, a raw incidence rate of 4.86 patients per 100,000 patient-years was found with an adjusted rate of 5.16 per 100,000 patient-years.

Conclusions This was a relatively short observational study (1-2 years). MG identification relied on billing diagnoses and was limited primarily to Medicaid and commercially insured patients, therefore older patients are likely underrepresented. However, the validity of the datasets used in this analysis give particular strength to the prevalence, incidence, and demographics observed in this study, which support the need for continued research in MG.

Authors/Disclosures
Jennifer Schwinn PRESENTER	Jennifer Schwinn has received personal compensation for serving as an employee of Immunovant, Inc..
Paola Mina-Osorio, MD, PhD (Immunovant)	Dr. Mina-Osorio has received personal compensation for serving as an employee of Immunovant. Dr. Mina-Osorio has stock in Immunovant, Inc..
Joel Arackal (University of Health Sciences and Pharmacy)	No disclosure on file
Jingyu Wang	No disclosure on file
Brett Venker (Roivant Sciences)	No disclosure on file

��ɫ��

��ɫ��